Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $10.0 million.

  • Nurix Therapeutics' Non-Current Deffered Revenue fell 6180.03% to $10.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was $10.0 million, marking a year-over-year decrease of 6180.03%. This contributed to the annual value of $10.0 million for FY2025, which is 6180.03% down from last year.
  • Nurix Therapeutics' Non-Current Deffered Revenue amounted to $10.0 million in Q4 2025, which was down 6180.03% from $15.2 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Non-Current Deffered Revenue registered a high of $77.7 million during Q1 2021, and its lowest value of $10.0 million during Q4 2025.
  • For the 5-year period, Nurix Therapeutics' Non-Current Deffered Revenue averaged around $37.5 million, with its median value being $35.2 million (2022).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 7534.66% in 2023, then surged by 19149.66% in 2024.
  • Nurix Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $59.0 million in 2021, then crashed by 39.05% to $36.0 million in 2022, then rose by 25.15% to $45.0 million in 2023, then plummeted by 41.79% to $26.2 million in 2024, then crashed by 61.8% to $10.0 million in 2025.
  • Its Non-Current Deffered Revenue was $10.0 million in Q4 2025, compared to $15.2 million in Q3 2025 and $21.6 million in Q2 2025.